Pillar Biosciences
Cancer Centers Look to New NGS-Based 'Frankenpanel' to Get Fast Info on Clinically Actionable Genes
Premium
Memorial Sloan Kettering Cancer Center is among the first healthcare systems to implement the rapid sequencing assay, which can consolidate single-gene tests.
Pillar Biosciences, AstraZeneca Partner on Liquid Biopsy Testing in Europe
AstraZeneca has partnered with several other firms on liquid biopsies, including Angle, Sophia Genetics, IMBdx, and Guardant Health.
FDA Approves Pillar Biosciences Pan-Cancer NGS Test for Solid Tumor Profiling
Previously approved for guiding EGFR- and KRAS-targeted therapy in specific tumor types, OncoReveal CDx can now be sold for general solid tumor profiling.
Illumina, Pillar Biosciences Ink Global Distribution Agreement for Cancer Dx Assays
The firms said their distribution deal will facilitate the integration of Pillar's precision oncology assays and Illumina's sequencers.
Pillar Biosciences Receives China Approval for Colon Cancer Companion Diagnostic Assay
The OncoReveal Dx Colon Cancer Assay is intended for use on the Illumina MiSeq Dx, and now has approvals in China, the US, and Europe.